Medicenna Therapeutics Corp.
MDNAF
$1.15
$0.054.55%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.98M | 4.31M | 4.29M | 5.02M | 5.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.60M | 15.68M | 14.65M | 13.63M | 13.48M |
| Operating Income | -15.60M | -15.68M | -14.65M | -13.63M | -13.48M |
| Income Before Tax | -9.99M | -9.50M | -8.59M | -19.73M | -19.68M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.99 | -9.50 | -8.59 | -19.73 | -19.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.99M | -9.50M | -8.59M | -19.73M | -19.68M |
| EBIT | -15.60M | -15.68M | -14.65M | -13.63M | -13.48M |
| EBITDA | -15.57M | -15.65M | -14.63M | -13.62M | -13.47M |
| EPS Basic | -0.12 | -0.12 | -0.11 | -0.27 | -0.28 |
| Normalized Basic EPS | -0.08 | -0.07 | -0.07 | -0.17 | -0.17 |
| EPS Diluted | -0.12 | -0.12 | -0.11 | -0.27 | -0.28 |
| Normalized Diluted EPS | -0.08 | -0.07 | -0.07 | -0.17 | -0.17 |
| Average Basic Shares Outstanding | 322.13M | 315.56M | 306.66M | 298.11M | 289.74M |
| Average Diluted Shares Outstanding | 322.13M | 315.56M | 306.66M | 298.11M | 289.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |